A Phase 2, Open-Label Study to Evaluate the Safety, Tolerability, and Efficacy of Subcutaneous Dose Levels of rAvPAL-PEG Administered Daily in Subjects With Phenylketonuria
Phase of Trial: Phase II
Latest Information Update: 28 Feb 2019
Price : $35 *
At a glance
- Drugs Pegvaliase (Primary)
- Indications Phenylketonuria
- Focus Therapeutic Use
- Sponsors BioMarin Pharmaceutical
- 18 Jul 2018 Results from (NCT00634660, NCT01560286, NCT00925054, NCT01212744, NCT00924703, NCT01819727 and NCT01889862) published in the BioDrugs
- 24 Jul 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 26 Feb 2015 Planned End Date changed from 1 Mar 2015 to 1 Jul 2015 according to ClinicalTrials.gov record.